# Marijuana Now Tops Alcohol and Cigarettes in Daily U.S. Use, Federal Data Shows > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/marijuana-now-tops-alcohol-and-cigarettes-in-daily-u-s-use-federal-data-shows/ > **Published:** 2026-07-29T17:10:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:13-04:00 > **Clinical Summary:** Daily cannabis use now exceeds alcohol use. Learn evidence-based screening and risk assessment for adolescents and young adults in clinical practice. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchSafety[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/)PediatricsNeurologyIndustry Why This Matters Daily [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) now exceeds daily alcohol and cigarette use in the U.S., representing a significant shift in [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) patterns that clinicians need to recognize when assessing patients’ health risks and [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) histories. Adolescents represent a particularly vulnerable population given evidence that regular marijuana exposure may impair neurodevelopment, making screening and prevention counseling essential components of pediatric and adolescent care. Clinicians should anticipate increased patient questions about [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) and efficacy while remaining prepared to address documented risks, particularly regarding cognitive effects and dependence potential in developing brains. Clinical Summary Federal surveillance data indicate that daily [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) now exceeds daily alcohol and tobacco use among American adults, representing a significant shift in [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) patterns that clinicians should recognize when conducting substance use screening and [risk assessment](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/). This epidemiological trend reflects both increased cannabis availability through legalization and changing social attitudes, creating a larger population of regular users whom clinicians will encounter across all specialties. The data are particularly concerning regarding adolescent users, as the developing brain remains vulnerable to cognitive and behavioral effects from regular or heavy cannabis exposure during critical neurodevelopmental windows. This population-level increase in daily use prevalence means clinicians should integrate [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) assessment into routine histories, particularly for adolescent and young adult patients, and counsel on risks including potential impacts on motivation, academic or occupational performance, and [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/). The normalization of cannabis in American society does not reduce the clinical imperative to understand individual patterns of use and associated harms. Clinicians should proactively discuss cannabis use with all patients, especially younger populations, to identify heavy users who may benefit from counseling or referral to behavioral health services. Dr. Caplan’s Take “What we’re seeing in the epidemiological data is a genuine shift in consumption patterns, and that deserves our attention, but I want to be careful about the framing: increased prevalence doesn’t automatically tell us about causation or individual risk, especially when we’re talking about adolescent neurodevelopment where the longitudinal evidence is still evolving. The concerning signals around heavy use in developing brains are real enough that we should take them seriously in clinical conversations, but we need population-level prospective studies to move beyond association and understand true attributable risk.” Clinical Perspective 💭 As cannabis use patterns shift toward greater frequency and normalization in the general population, clinicians should recognize that regular users now represent a substantial portion of their patient panels, requiring routine screening and [risk assessment](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/) during clinical encounters. The particular concern for adolescent neurodevelopment is well-founded given evidence of structural and functional brain changes associated with heavy early-use, though the clinical significance of these findings and their reversibility remain incompletely understood. A key confounding factor is that cannabis products have become vastly more potent over the past decade, and today’s typical user exposure differs markedly from historical patterns, making it difficult to extrapolate from older epidemiological studies. Additionally, the reasons driving increased use frequency are multifactorial—ranging from self-medication for anxiety and pain to pure recreational preference—and will influence both individual health risks and the counseling approach most appropriate for each patient. Clinicians should incorporate direct, non-judgmental questions about 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Marijuana%20Now%20Tops%20Alcohol%20and%20Cigarettes%20in%20Daily%20U.S.%20Use%2C%20Federal%20Data%20Shows%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71679)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71679)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Marijuana%20Now%20Tops%20Alcohol%20and%20Cigarettes%20in%20Daily%20U.S.%20Use%2C%20Federal%20Data%20Shows%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71679)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Digest: Cannabis Surpasses Cigarettes and Alcohol in the News Cycle](https://cedclinic.com/cannabis-news-cycle-2026-reporting-analysis/) 📰 Source: [https://stupiddope.com/2026/07/marijuana-now-tops-alcohol-and-cigarettes-in-daily-u-s-use-federal-data-shows/](https://stupiddope.com/2026/07/marijuana-now-tops-alcohol-and-cigarettes-in-daily-u-s-use-federal-data-shows/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).